Literature DB >> 29624549

Phase II Clinical Trial to Evaluate the Efficacy of Transanal Endoscopic Total Mesorectal Excision for Rectal Cancer.

Sung Chan Park1, Dae Kyung Sohn1, Min Jung Kim1, Hee Jin Chang1, Kyung Su Han1, Jong Hee Hyun1, Jungnam Joo2, Jae Hwan Oh1.   

Abstract

BACKGROUND: Total mesorectal excision has become the standard treatment for rectal cancer, and several investigators have shown that a transanal approach is a feasible option.
OBJECTIVE: This study aimed to evaluate the efficacy of transanal endoscopic total mesorectal excision in patients with rectal cancer.
DESIGN: This study was a prospective, single-arm phase II trial. It was registered on clinicaltrials.gov under identifier NCT02406118. SETTINGS: Inpatients at a hospital specializing in oncology were selected. PATIENTS: This prospective study enrolled 49 patients with rectal cancer located 3 to 12 cm from the anal verge who were scheduled to undergo radical surgery.
INTERVENTIONS: Laparoscopy-assisted transanal total mesorectal excision was performed. MAIN OUTCOME MEASURES: The primary end point was total mesorectal excision quality and circumferential resection margin. Secondary end points included the number of harvested lymph nodes, operation time, and 30-day postoperative complications.
RESULTS: From March 2015 to April 2016, 32 men and 17 women with rectal cancer were enrolled. The mean age was 61.2 years, and mean BMI was 23.3 kg/m. The mean operating time was 158 minutes, and the mean estimated blood loss was 89.3 mL. There were no intraoperative complications and no conversions to open surgery. Successful treatment based on total mesorectal excision quality and circumferential resection margin was achieved in 45 patients (91.8%). Fifteen patients (30.6%) had 30-day postoperative complications, including 7 (14.3%) with anastomotic dehiscence, 5 (10.2%) with urinary retention, 2 (4.1%) with abdominal wound complications, and 1 (2.0%) with ileus. There was no postoperative mortality. LIMITATIONS: This was a noncomparative single-arm trial conducted at a single institution.
CONCLUSIONS: Transanal endoscopic total mesorectal excision showed acceptable results based on perioperative and short-term oncologic outcomes. Further investigations are necessary to show the benefits and long-term outcomes of this procedure. See Video Abstract at http://links.lww.com/DCR/A563.

Entities:  

Mesh:

Year:  2018        PMID: 29624549     DOI: 10.1097/DCR.0000000000001058

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  4 in total

Review 1.  Limitations and Concerns with Transanal Total Mesorectal Excision for Rectal Cancer.

Authors:  M Vannijvel; Albert M Wolthuis
Journal:  Clin Colon Rectal Surg       Date:  2022-02-28

Review 2.  Colorectal Cancer Immunotherapy: Options and Strategies.

Authors:  Nor Adzimah Johdi; Nur Fazilah Sukor
Journal:  Front Immunol       Date:  2020-09-18       Impact factor: 7.561

3.  Role of salt‑inducible kinase 2 in the malignant behavior and glycolysis of colorectal cancer cells.

Authors:  Xiaohong Ni; Yongjiang Feng; Xiangwei Fu
Journal:  Mol Med Rep       Date:  2021-09-24       Impact factor: 2.952

4.  Comparison of patient-reported quality of life and functional outcomes following laparoscopic and transanal total mesorectal excision of rectal cancer.

Authors:  Ryun Kyong Ha; Sung Chan Park; Boram Park; Sung Sil Park; Dae Kyung Sohn; Hee Jin Chang; Jae Hwan Oh
Journal:  Ann Surg Treat Res       Date:  2021-06-30       Impact factor: 1.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.